Rx Medicare

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) announced that the screening of volunteers for inclusion in a Phase 2 clinical study of the company’s oral interferon product at the University of Western Australia is now complete. The investigators met their target of screening at least 200 healthy adults for participation in the trial. A total of 215 volunteers were evaluated and 134 of them have been enrolled into the study to date.

Read More…

Related Posts

• Amarillo Biosciences Announces Australian Phase 2 Oral Interferon Clinical Trial Indicates Benefit In Preventing Influenza-Like Illness In Seniors
• Amarillo Biosciences Reports On Research Supporting Use Of Interferon To Combat Influenza
• ImmuneRegen BioSciences(R) Reports Additional Positive Results From Study Of Homspera(R) In Treating Highly Pathogenic Influenza
• Implications Of Influenza Pandemics On Blood Supplies Highlighted By Study
• Vaccination, Antivirals And Social Distancing May Blunt Impact Of H1N1 Influenza, Finds Epidemiological Modelling Study
• NanoViricides Presents FluCide™ Animal Study Data At Influenza Congress – Now Improved Substantially And Vastly Superior To Current Treatment
• Amarillo Biosciences Comments On New Findings Of H1N1 In Animals And Potential Effect On Human Infections
• New Study Evaluates Surgical Masks Vs. N95 Respirators For Preventing Influenza Among Health Care Workers
• Antiviral Guidelines And Rapid Tests For Diagnosing Influenza Available On National Prescribing Service Website, Australia
• Study Documents Increasing Prevalence Of Influenza A Resistance To Drug Oseltamivir
• Authoritative New Study Reveals Global Pandemic Influenza Vaccine Capacity
• Workplace Benefits Of Influenza Vaccination In 50-64 Year Olds Shown By Study
• Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
• Pharmacy Swine Flu Trial Moves Into Phase II – Pharmaceutical Society Of Australia
• Vaccinating Kids Against Flu Protects Whole Community, Canadian Study

Tags: amarillo, australia, biosciences, completion, efficacy, influenza, process, screening, study

This entry was posted on Wednesday, June 24th, 2009 at 3:06 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.